Doctor's Bio
Mehmet Asim Bilen, MD, serves as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bilen joined the clinical staff at Grady’s Cancer Center as a practicing physician in July 2016. He is actively involved in clinical research and patient care in the area of genitourinary cancers. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Grady Clinical Research Committee. Dr. Bilen holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: Hacettepe University Medical School
- Internship: Baylor College of Medicine
- Residency: Baylor College of Medicine
Fellowships
University of Texas MD Anderson Cancer Center
Locations and Directions
Correll Pavilion
Phone: (404) 616-1000
Location:
80 Gilmer St. SE
Atlanta, GA 30303
Publications
- Therapeutic targeting of Aurora Kinase A in advanced prostate cancer.
Zerdan MB, Bilen MA, Yu J
Serican journal of medicine. 2025;
PMID: 41658018 - Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.
Jang A, Jindal T, Khaki AR, Jiang CY, Alhalabi O, Nguyen CB, Tsung I, Oh E, Epstein I, Bakaloudi DR, Jaime-Casas S, Nizam A, Glover M, Mabey H, Taylor A, Evans S, Shin D, Pywell C, Abuqayas B, Barata PC, Zakharia Y, Basu A, Kilari D, Bilen MA, Emamekhoo H, Milowsky M, Hoimes CJ, Davis N, Shah S, Gupta S, Tripathi A, Grivas P, Bellmunt J, Alva A, Campbell MT, Chen Z, Fu P, Koshkin VS, Brown JR
Clinical genitourinary cancer. 2026;
PMID: 41644316 - Clinical outcomes of Lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.
Gerke MB, Bedmutha A, Marra A, Liu Y, Brown JT, Nazha B, Berchuck JE, Parikh RB, Ahmed S, Ciuro JA, Hartman C, McClintock GR, Caulfield S, Kucuk O, Carthon BC, Schuster DM, Muzahir S, Bilen MA
The oncologist. 2026;
PMID: 41630499 - Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancer.
Bilen MA, Shore N, Burbage S, Rossi C, Diaz L, Khilfeh I, Wang Y, Wong G, Pilon D, Brown G, Lowentritt B, Lin DW
Urology. 2026;
PMID: 41620128 - Erratum: Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance.
Lahiji R, Morton EA, Ramacciotti LS, Nicaise EH, Marthi S, Schmeusser BN, Abdollahzadeh A, Palmateer GS, Vashi K, Goyal S, Liu Y, Midenberg E, Patil D, Harvey RD, Connor MJ, Hajiha M, Ogan K, Bilen MA, Master VA
JCO oncology practice. 2026;
PMID: 41505671 - An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.
Palmateer G, Yildirim A, Goodstein T, Patil D, Patel S, Joshi S, Narayan V, Brown JT, Nazha B, Ahmed SS, Ciuro J, Carthon BC, Kucuk O, Kissick H, Ogan K, Bilen MA, Master VA
The oncologist. 2026;
PMID: 41495002 - Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.
Rhee CH, Goyal S, Liu Y, Martini DJ, Shabto JM, Nazha B, Kucuk O, Carthon BC, Bilen MA, Brown JT
The oncologist. 2025;
PMID: 41442452 - [F]-Fluciclovine or [Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.
Jani AB, Dhere VR, Goyal S, Schreibmann E, Patel PR, Hershatter B, Shelton JW, Hanasoge S, Sebastian NT, Patel SA, Halkar R, Cooper S, Fielder B, Abiodun-Ojo OA, Lawal I, Mushtaq A, Master VA, Joshi SS, Kucuk O, Bilen MA, Schuster DM
European urology. 2025;
PMID: 41412908 - Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.
Wummer B, Schwartz M, Ciuro J, Ahmed S, Joshi SS, Narayan VM, Carthon BC, Bilen MA, Brown JT
Frontiers in oncology. 2025;
PMID: 41409251 - Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance.
Lahiji R, Morton EA, Storino Ramacciotti L, Nicaise EH, Marthi S, Schmeusser BN, Abdollahzadeh A, Palmateer GS, Vashi K, Goyal S, Liu Y, Midenberg E, Patil D, Harvey RD, Connor MJ, Hajiha M, Ogan K, Bilen MA, Master VA
JCO oncology practice. 2025;
PMID: 41401405
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.